110 related articles for article (PubMed ID: 24984547)
1. Serum and tissue level of YKL-40 in endometrial cancer.
Fan JT; Li MJ; Shen P; Xu H; Li DH; Yan HQ
Eur J Gynaecol Oncol; 2014; 35(3):304-8. PubMed ID: 24984547
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer.
Fan JT; Si XH; Liao Y; Shen P
Arch Gynecol Obstet; 2013 Jan; 287(1):111-5. PubMed ID: 22945838
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum levels of YKL 40 and CA125 as a prognostic indicators in patients with endometrial cancer.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Wagrodzki M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():141-147. PubMed ID: 28624692
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer.
Kemik P; Saatli B; Yıldırım N; Kemik VD; Deveci B; Terek MC; Koçtürk S; Koyuncuoğlu M; Saygılı U
Gynecol Oncol; 2016 Jan; 140(1):64-9. PubMed ID: 26607777
[TBL] [Abstract][Full Text] [Related]
6. Early detection and prognosis of ovarian cancer using serum YKL-40.
Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
[TBL] [Abstract][Full Text] [Related]
7. Discordance between serum level and tissue immunohistochemical staining of CA125 in endometrioid adenocarcinoma of the uterine corpus.
Yamazawa K; Hirashiki K; Usui H; Mitsuhashi A; Matsui H; Sekiya S
Int J Gynecol Pathol; 2005 Jul; 24(3):254-9. PubMed ID: 15968201
[TBL] [Abstract][Full Text] [Related]
8. YKL-40 tissue expression and plasma levels in patients with ovarian cancer.
Høgdall EV; Ringsholt M; Høgdall CK; Christensen IJ; Johansen JS; Kjaer SK; Blaakaer J; Ostenfeld-Møller L; Price PA; Christensen LH
BMC Cancer; 2009 Jan; 9():8. PubMed ID: 19134206
[TBL] [Abstract][Full Text] [Related]
9. YKL-40 protein levels and clinical outcome of human endometrial cancer.
Peng C; Peng J; Jiang L; You Q; Zheng J; Ning X
J Int Med Res; 2010; 38(4):1448-57. PubMed ID: 20926018
[TBL] [Abstract][Full Text] [Related]
10. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis.
Kazakova M; Batalov A; Deneva T; Mateva N; Kolarov Z; Sarafian V
Rheumatol Int; 2013 Feb; 33(2):341-6. PubMed ID: 22451025
[TBL] [Abstract][Full Text] [Related]
11. Serum YKL-40 is increased in patients with hepatic fibrosis.
Johansen JS; Christoffersen P; Møller S; Price PA; Henriksen JH; Garbarsch C; Bendtsen F
J Hepatol; 2000 Jun; 32(6):911-20. PubMed ID: 10898311
[TBL] [Abstract][Full Text] [Related]
12. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
Høgdall EV; Johansen JS; Kjaer SK; Price PA; Christensen L; Blaakaer J; Bock JE; Glud E; Høgdall CK
Oncol Rep; 2003; 10(5):1535-8. PubMed ID: 12883737
[TBL] [Abstract][Full Text] [Related]
13. Tissue and serum CA125 expression in endometrial cancer.
Ginath S; Menczer J; Fintsi Y; Ben-Shem E; Glezerman M; Avinoach I
Int J Gynecol Cancer; 2002; 12(4):372-5. PubMed ID: 12144685
[TBL] [Abstract][Full Text] [Related]
14. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer.
Özdemir E; Çiçek T; Kaya MO
Urol J; 2012; 9(3):568-73. PubMed ID: 22903479
[TBL] [Abstract][Full Text] [Related]
15. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
16. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
17. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
[TBL] [Abstract][Full Text] [Related]
18. Analysis of YKL-40 acute-phase protein and interleukin-6 levels in periodontal disease.
Keles ZP; Keles GC; Avci B; Cetinkaya BO; Emingil G
J Periodontol; 2014 Sep; 85(9):1240-6. PubMed ID: 24635545
[TBL] [Abstract][Full Text] [Related]
19. Serum YKL-40 as a marker for cervical adenocarcinoma.
Mitsuhashi A; Matsui H; Usui H; Nagai Y; Tate S; Unno Y; Hirashiki K; Seki K; Shozu M
Ann Oncol; 2009 Jan; 20(1):71-7. PubMed ID: 18723551
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
Zou L; He X; Zhang JW
Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
